Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | ArrowMark Colorado Holdings, LLCMeridian Growth Fund | Royalty Pharma $RPRX• NASDAQ | BiotechnologyBiotechnology | Long RPRX (Royalty Pharma) Royalty Pharma plc is the industry's largest buyer of biopharmaceutical royalties, partnering with innovators to co-fund late-stage clinical trials and acquiring existing royalties on approved therapi | BULL | View Pitch → |
| Aug 21, 2026 | Fund Letter | Christina Siegel MalbonPatient Capital Management | Royalty Pharma $RPRX• NASDAQ | BiotechnologyBiotechnology | Long RPRX (Royalty Pharma) Royalty Pharma offers highly defensive, diversified royalty income streams at a very low valuation of 5.9x forward earnings. Led by a... | BULL | View Pitch → |
| Feb 20, 2026 | Fund Letter | Freddie LaitLatitude Global Fund | Royalty Pharma $RPRX• NASDAQ | BiotechnologyBiotechnology | Latitude Global Fund 2025 Q4 (RPRX) Thirty years later, the company he founded, Royalty Pharma, generates over $2bn per year in cash flow, produced by royalties on a highly diversified collection of drugs, including 7 of the top 30 in the US. The company has... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.